TRENBOLONE HEXAHYDROBENZYLCARBONATE

TRENBOLONE HEXAHYDROBENZYLCARBONATE USP 75 mg
Oil Base q.s.
Presented as box with 10 ml vial (multidose)

DESCRIPTION

Trenbolone HEXAHYDROBENZYLCARBONATE is a man-made steroid, similar to the naturally occurring steroid-testosterone.

INDICATIONS

Males: Androgen Replacement Therapy.
Trenbolone Hexa is used to promote weight gain following extensive surgery, chronic infection, or severe trauma, and in other cases that result in inadequate weight gain or maintenance.
Trenbolone Hexa is also used to decrease muscle loss caused by treatment with corticosteroids and to reduce bone pain associated with osteoporosis

CONTRAINDICATIONS

1. Diagnosed or suspected carcinoma of the male breast or prostate.
2. Women who are pregnant or may become pregnant because of possible masculinization of the fetus. When administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus. This virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure.
3. Patients with a history of hypersensitivity to Trenbolone Hexa or any of its components.
4. Patients with serious renal, cardiac, or hepatic dysfunction.

PRECAUTIONS

General: Women should be observed for signs of virilization. Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease. All patients: Any nausea, vomiting, changes in skin color or ankle swelling.

DOSAGE AND ADMINISTRATION

In males with delayed puberty: Various dosage regimens have been used; some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance levels. Other regimens call for higher dosage to induce pubertal changes and lower dosage for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose.
Dosage is within the range of 50 to 200 mg every 2 to 4 weeks for a limited duration, for example, 4 to 6 months. X-rays should be taken at appropriate intervals to determine the amount of bone maturation.
Palliation of inoperable mammary cancer in woman: A dosage of 200 to 400 mg every 2 to 4 weeks is recommended. Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease.

PRESENTATION

75 mg/ml, 1 x 10 ml vial

STORAGE

Store in a cool dry place (30 °C E 2 °C). Protect from light.

Warming and rotating the ampoule between the palms of the hands will redissolve any crystals that may have been formed during storage at low temperatures